ClinicalTrials.gg
Active, not recruitingNCT04337177Updated Jul 30, 2026

Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors

A Phase 1 interventional study of VAL-413 and Temozolomide in Solid Tumors, Neuroblastoma and Rhabdomyosarcoma, sponsored by Valent Technologies, LLC. Active, not recruiting at 11 sites in United States. Open to participants aged 1 Year to 30 Years. Per ClinicalTrials.gov, last updated 2026-07-30.

Primary conditionnone(registry's first term: Neuroblastoma)Many cancersIs this wrong?The study is open to many cancers (its listed conditions name solid tumors in general), and its title does not single out Neuroblastoma, so we do not take that as its main condition. It is not compared with other studies by condition.

Sponsored by Valent Technologies, LLC · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Non-randomized
Ages
1 Year to 30 Years
Sex
All
01

Study summary

A pilot pharmacokinetic trial to determine the safety and efficacy of a flavored, orally administered irinotecan VAL-413 (Orotecan®) given with temozolomide for treatment of recurrent pediatric solid tumors including but not limited to neuroblastoma, rhabdomyosarcoma, Ewing sarcoma, hepatoblastoma and medulloblastoma

Read the detailed description

Up to 20 patients ≥ 1 year of age or ≤ 30 years of age with recurrent pediatric solid tumors will be enrolled. During the first cycle of treatment, each patient will receive 4 daily doses of VAL-413 (Orotecan®) and one daily dose of the intravenous preparation of irinotecan taken orally (IRN-IVPO), together with 5 days of concurrent temozolomide. During all subsequent cycles, only Orotecan® will be given with temozolomide in 5 day courses administered every 21 days as tolerated.

The dosing regimen in this study will be Temozolomide at 100 mg/m2/day with Orotecan® at either 90 or 110mg/m2/day, administered orally for 5 consecutive days at the beginning of every 21-day cycle. A single dose of IRN-IVPO will be substituted at the same dosage as Orotecan® during Cycle 1. Up to 17 cycles of treatment may be administered on this study.

Data collected from this study will allow for an assessment of Orotecan® safety and efficacy. Interval medical histories, targeted physical exams, complete blood counts, and other laboratory and safety assessments will be performed at Day 1 of each treatment cycle for all study subjects. At baseline and during study, disease status will be assessed by appropriate clinical and imaging evaluation (CT, MRI, or PET) and using Response Evaluation Criteria in Solid Tumors (RECIST), International Neuroblastoma Response Criteria (INRC) for patients with neuroblastoma, or the Children's Oncology Group Response Criteria for CNS tumors. In addition, a single-response taste survey will be conducted on Day 1 and Day 4 of the first cycle, which will allow patients to evaluate the taste of Orotecan®. Serum samples will be collected at various time points on Days 1 and 4 during Cycle 1 to characterize and compare the pharmacokinetic profiles of Orotecan® and conventional irinotecan given orally.

Assessment of first-cycle toxicity will be used to identify the recommended phase II dose for Orotecan®. Toxicity will be evaluated and documented using NCI CTCAE guidelines. The recommended Phase II dose will be identified as the highest dose at which no more than 1 of 6 patients experiences a first cycle dose limiting toxicity (DLT). Additional study subjects may be enrolled at the recommended Phase II dose to ensure balanced safety and pharmacokinetic data is obtained for at least 3 patients \< 12 years old and at least 3 patients > 12 years old.

02

Conditions studied

  • Solid Tumors
  • Neuroblastoma
  • Rhabdomyosarcoma
  • Ewing Sarcoma
  • Hepatoblastoma
  • Medulloblastoma

Keywords

  • irinotecan
  • pediatric
  • solid tumor
  • neuroblastoma
  • rhabdomyosarcoma
  • Ewing sarcoma
  • hepatoblastoma
  • medulloblastoma
  • recurrent
03

In context

Lead sponsor

This is the only study on the registry with Valent Technologies, LLC as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Year to 30 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients must be 1 year of age to ≤ 30 years of age at the time of study entry.
  2. Patients must have had histologic verification of a solid tumor or CNS tumor at either original diagnosis or relapse.
  3. Measurable or evaluable disease is not required for enrollment on this safety/feasibility study.
  4. Patient's current disease state must be one for which there is no known curative therapy or therapy proven to prolong survival with an acceptable quality of life or for which irinotecan and/or temozolomide are acceptable therapeutic options based on existing standard of care available.
  5. Performance Status ≥ 50% for patients > 16 years of age and Lansky Performance Status ≥ 50 for patients ≤ 16 years of age. Patients who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score.
  6. Males or females of may not participate unless they have agreed to use an effective method during and for 30 days after study treatment. (Abstinence is considered an acceptable method of effective contraception.)
  7. Prior treatment with temozolomide, vincristine or irinotecan is allowed, although patients must not have had disease progression while receiving either irinotecan, vincristine or temozolomide.
  8. Patients must have recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study, as described below:

    1. Myelosuppressive chemotherapy: patients must not have received myelosuppressive chemotherapy within 21 days of first study treatment, but nitrosourea within 8 weeks (42 days) of first study treatment
    2. Anti-cancer agents not known to be myelosuppressive (e.g., not associated with drops in or ): must not have received these therapies within 7 days of first study treatment, or at least 5 half-lives of the agent (whichever is longer)
    3. Antibody therapy: At least 4 weeks must have elapsed since last antibody dose prior to first study treatment
    4. Radiation therapy: At least two weeks must have elapsed since last local palliative radiation (small port) prior to first study treatment. At least 6 weeks must have elapsed if more substantial radiation was administered (e.g., >50% pelvis, craniospinal, whole body), or therapeutic radiolabeled 131I MIBG or other radiopharmaceutical therapy.
    5. High-Dose Chemotherapy with Stem Cell Transplant/Rescue: At least two months must have elapsed since receiving autologous hematopoietic stem cells prior to first study treatment. Patients who have had allogeneic transplants are ineligible.
    6. Hematopoietic growth factors: must not have been received in the 14 days prior to first study treatment for a long-acting growth factor (e.g., pegfilgrastim), or 7 days prior to first study treatment for short-acting growth factor.
  9. Peripheral absolute neutrophil count (ANC) ≥ 1,000/µL
  10. Platelet count ≥100,000/µL (transfusion independent, defined as not receiving platelet transfusions within a 7-day period prior to first study treatment)
  11. ≥ 8.0 gm/dL (may receive RBC transfusions) NOTE: Patients with tumor in the bone marrow ARE eligible provided the above hematologic criteria are met.
  12. or radioisotope ≥ 70mL/min/1.73 m2 or Serum creatinine based on age/gender as follows:

    Age Maximum Serum Creatinine (mg/dL) Male Female 1 to \< 2 years 0.6 0.6 2 to \< 6 years 0.8 0.8 6 to \< 10 years 1 1 10 to \< 13 years 1.2 1.2 13 to \< 16 years 1.5 1.4

    ≥ 16 years 1.7 1.4

    The threshold creatinine values in this Table were derived from the Schwartz formula for estimating GFR (Schwartz et al. J. Peds, 106:522, 1985) utilizing child length and stature data published by the CDC.

  13. (sum of conjugated + unconjugated) ≤ 1.5 x (ULN) for age
  14. (ALT) ≤ 5 x upper limit of normal (ULN) for age
  15. Serum albumin ≥ 2 g/dL

Exclusion criteria

Exclusion Criteria:

  1. Patients with a history of severe allergic reaction (e.g., more than simple rash) to dacarbazine or third-generation cephalosporins are ineligible.
  2. Pregnant or breast-feeding women will not be entered on this study due to potential risks of fetal and teratogenic adverse events. A pregnancy test must be obtained prior to starting chemotherapy in post-menarchal female patients.
  3. Patients who are currently receiving drugs, or who have received an investigational drug within the last 7 days prior to first study treatment, are ineligible.
  4. Patients who are currently receiving other anti-cancer agents are ineligible.
  5. Patients taking strong inducers of , including but not limited to phenobarbital, phenytoin, carbamazepine, oxcarbazepine (Trileptal), rifampin, voriconazole, itraconazole, ketoconazole or other systemically-administered azole antifungal drugs, aprepitant (Emend) or St. John's Wort, in the 2 weeks prior to first study treatment are ineligible.
  6. Patients taking strong inhibitors of CYP3A4 or UGT1A1 in the 1 week prior to first study treatment are ineligible.
  7. Patients must not be receiving medications known to inhibit function or known to selectively inhibit cyclooxygenase activity. Medicines in this class are excluded, with the exception of acetaminophen.
  8. Patients who have uncontrolled infections, require IV antibiotics at time of enrollment, or who are currently receiving treatment for Clostridium difficile infection are excluded.
  9. Patients who in the opinion of the investigator may not be able to comply with the safety monitoring requirements of the study are not eligible.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    90 mg/m2/day VAL-413 (Orotecan®)

    Orotecan® at 90 mg/m2/day administered with Temozolomide at 100 mg/m2/day orally for 5 consecutive days at the beginning of every 21-day cycle. A single dose of the intravenous preparation of irinotecan taken orally (IRN-IVPO) will be substituted at the same dosage as Orotecan® for during Cycle 1.

    Drug: VAL-413 · Drug: Temozolomide

  • Experimental
    110 mg/m2/day VAL-413 (Orotecan®)

    Orotecan® at 110 mg/m2/day administered with Temozolomide at 100 mg/m2/day orally for 5 consecutive days at the beginning of every 21-day cycle. A single dose of the intravenous preparation of irinotecan taken orally (IRN-IVPO) will be substituted at the same dosage as Orotecan® for during Cycle 1.

    Drug: VAL-413 · Drug: Temozolomide

  • Experimental
    75 mg/m2/day VAL-413 (Orotecan®)

    In the event the 90 mg/m2/day starting dose is not tolerable due to toxicity, a lower starting dose of 75 mg/m2/day may be implemented. Orotecan® at 75 mg/m2/day administered with Temozolomide at 100 mg/m2/day orally for 5 consecutive days at the beginning of every 21-day cycle. A single dose of the intravenous preparation of irinotecan taken orally (IRN-IVPO) will be substituted at the same dosage as Orotecan® for during Cycle 1.

    Drug: VAL-413 · Drug: Temozolomide

Interventions

  • DrugVAL-413

    a flavored preparation of orally administered irinotecan

    Also known as: Orotecan®

  • alkylating oral chemotherapy agent used to treatment brain cancers

    Also known as: Temodar, Temodal, Temcad, TMZ

06

What researchers measure

Primary outcomes

  1. Recommended Phase II Dose (RP2D)

    To establish the recommended Phase II dose of a flavored preparation of orally administered irinotecan VAL-413 (Orotecan®) when given in combination with temozolomide for 5 consecutive days

    Time frame: 17 months

Secondary outcomes

  1. Cmax

    Maximum observed concentration of VAL-413 (Orotecan®) on Day 1

    Time frame: 1 day

  2. Tmax

    Time of observed VAL-413 (Orotecan®) Cmax on Day 1

    Time frame: 1 day

  3. AUClast

    Area under the concentration-time curve from pre-dose (time 0) to the time of the last quantifiable VAL-413 (Orotecan®) concentration on Day 1

    Time frame: 1 day

  4. AUCinf

    Area under the concentration-time curve for VAL-413 (Orotecan®) extrapolated to infinity on Day 1

    Time frame: 1 day

  5. CL/F

    Total oral body clearance at steady state calculated as VAL-413 (Orotecan®) dose/AUC on Day 1

    Time frame: 1 day

  6. MRT

    Mean Residence Time for VAL-413 (Orotecan®) calculated as AUMC/AUC where AUMC is Area under the Moment Curve

    Time frame: 1 day

  7. Vz

    The apparent volume of distribution for VAL-413 (Orotecan®) during the terminal phase

    Time frame: 1 day

  8. Lambda z

    The terminal elimination rate constant determined by selection of at least three decreasing data points on the terminal phase of the concentration time curve for VAL-413 (Orotecan®) on Day 1

    Time frame: 1 day

  9. T1/2

    Terminal elimination half-life of VAL-413 (Orotecan®) on Day 1 determined from 0.693/Lambda z

    Time frame: 1 day

  10. Palatability

    To evaluate the palatability of VAL-413 (Orotecan®) using a proprietary Valent Taste Survey which allows pediatric patients or their parents to rate how agreeable they find the flavor of VAL-413 (Orotecan®), on scale from 7, Like Very Much down to 1, Dislike Very Much

    Time frame: 1 month

  11. Adverse Events

    To assess the toxicity profile of this combination therapy using NCI CTCAE guidelines

    Time frame: 17 months

  12. Treatment Response

    To assess treatment response using the Response Evaluation Criteria in Solid Tumors (RECIST) guideline, or for patients with neuroblastoma, the International Neuroblastoma Response Criteria (INRC) guideline

    Time frame: 17 months

07

Study locations

11 sites
  • Phoenix Children's Hospital
    Phoenix, Arizona 85016, United States
  • UCSF, Mission Bay - Benioff Children's Hospital
    San Francisco, California 94143, United States
  • Children's National Research Institute - Children's National Hospital
    Washington D.C., District of Columbia 20010, United States
  • Children's Healthcare of Atlanta - Arthur M. Blank Hospital
    Atlanta, Georgia 30329, United States
  • Indiana University School of Medicine, Riley Hospital for Children
    Indianapolis, Indiana 46202, United States
  • Washington University - St. Louis
    St Louis, Missouri 63110, United States
  • University of North Carolina at Chapel Hill - North Carolina Cancer Hospital
    Chapel Hill, North Carolina 27514, United States
  • Atrium Health Levine Children's Hospital - Carolinas Medical Center
    Charlotte, North Carolina 28204, United States
  • Duke University Children's Hospital and Health Center
    Durham, North Carolina 27710, United States
  • Cincinnati Children's Hospital Medical Center
    Cincinnati, Ohio 45229-3039, United States
  • Sarah Cannon Research Institute, Pediatric Hematology & Oncology
    Nashville, Tennessee 37203, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2021 (actual). Primary completion is estimated for Dec 2026, 62 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 30, 2020
First posted
Apr 7, 2020
StartActual
Oct 25, 2021
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Jul 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04337177
Lead sponsor
Valent Technologies, LLC
Responsible party
Sponsor
First posted
Apr 7, 2020
Start date
Oct 25, 2021
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Jul 30, 2026

Study contacts

Lars Wagner, M.D.
principal investigator · Children's Hospital Medical Center, Cincinnati
Michael Deel, M.D.
principal investigator · Children's Hospital Medical Center, Cincinnati
Meghann McManus, D.O.
principal investigator · Sarah Cannon Research Institute, Pediatric Hematology & Oncology
Erin Trovillion, M.D.
principal investigator · Atrium Health Levine Children's Hospital - Carolinas Medical Center
Patrick Thompson, M.D.
principal investigator · UNC Chapel Hill - North Carolina Cancer Hospital
Aerang Kim, M.D.
principal investigator · Children's National Hospital - Washington, DC
Kieuhoa Vo, M.D.
principal investigator · UCSF - Mission Bay, Benioff Children's Hospital
Kyle Jackson, M.D.
principal investigator · Indiana University School of Medicine, Riley Hospital for Children
William Thomas Cash, M.D.
principal investigator · Children's Healthcare of Atlanta - Arthur M. Blank Hospital
Alok Kothari, M.D.
principal investigator · Phoenix Children's Hospital
Mia Weiss, M.D.
principal investigator · Washington University School of Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion